ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
2.
McDonaldWIMillerDHThompsonAJ.Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. Ann Neurol1994; 36(1): 14–18.
3.
O’RiordanJIThompsonAJKingsleyDP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain1998; 121(Pt. 3): 495–503.
4.
FilippiMPreziosaPMeaniA, et al. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol2018; 17(2): 133–142.
5.
SormaniMPBruzziP.MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol2013; 12(7): 669–676.
6.
BrownJWLColesAHorakovaD, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA2019; 321(2): 175–187.
7.
RíoJRoviraATintoréM, et al. Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. Mult Scler2018; 24(3): 322–330.
8.
TintoreMRoviraAArrambideG, et al. Brainstem lesions in clinically isolated syndromes. Neurology2010; 75(21): 1933–1938.
9.
TallantyreECCausonEGHardingKE, et al. The aetiology of acute neurological decline in multiple sclerosis: experience from an open-access clinic. Mult Scler2015; 21(1): 67–75.
10.
GeurtsJJBöLPouwelsPJCastelijnsJA, et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol2005; 26(3): 572–577.
